| 1 |
33804018 | Characterization of P-Glycoprotein Inhibitors for Evaluating the Effect of P-Glycoprotein on the Intestinal Absorption of Drugs. | 2021 Mar 15 |
2 |
| 2 |
28830790 | Increased delivery of chemotherapy to the vitreous by inhibition of the blood-retinal barrier. | 2017 Oct 28 |
2 |
| 3 |
29212189 | Quizartinib (AC220) reverses ABCG2-mediated multidrug resistance: In vitro and in vivo studies. | 2017 Nov 7 |
1 |
| 4 |
26199091 | ABCG2 Transporter Expression Impacts Group 3 Medulloblastoma Response to Chemotherapy. | 2015 Sep 15 |
3 |
| 5 |
26515463 | A-803467, a tetrodotoxin-resistant sodium channel blocker, modulates ABCG2-mediated MDR in vitro and in vivo. | 2015 Nov 17 |
2 |
| 6 |
23635651 | Overlapping functions of ABC transporters in topotecan disposition as determined in gene knockout mouse models. | 2013 Jul |
1 |
| 7 |
23028879 | EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumors. | 2012 |
2 |
| 8 |
21309545 | Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier. | 2011 Apr 4 |
2 |
| 9 |
21718946 | Evaluation of the P-glycoprotein- and breast cancer resistance protein-mediated brain penetration of 11C-labeled topotecan using small-animal positron emission tomography. | 2011 Jul |
1 |
| 10 |
20145144 | Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan. | 2010 Feb 15 |
2 |
| 11 |
19567673 | Compartment-specific roles of ATP-binding cassette transporters define differential topotecan distribution in brain parenchyma and cerebrospinal fluid. | 2009 Jul 15 |
5 |
| 12 |
19802874 | ABCG2-associated resistance to Hoechst 33342 and topotecan in a murine cell model with constitutive expression of side population characteristics. | 2009 Nov |
2 |
| 13 |
18523872 | Characterization of substrates and inhibitors for the in vitro assessment of Bcrp mediated drug-drug interactions. | 2008 Oct |
1 |
| 14 |
19047120 | Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial data. | 2008 Dec 1 |
3 |
| 15 |
17975156 | P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan. | 2007 Nov 1 |
5 |
| 16 |
16651435 | Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo. | 2006 May 1 |
1 |
| 17 |
17145877 | Topotecan central nervous system penetration is altered by a tyrosine kinase inhibitor. | 2006 Dec 1 |
1 |
| 18 |
15685169 | The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk. | 2005 Feb |
1 |
| 19 |
14566825 | Single amino acid substitutions in the transmembrane domains of breast cancer resistance protein (BCRP) alter cross resistance patterns in transfectants. | 2003 Dec 10 |
1 |
| 20 |
11956086 | A mutation hot spot in the Bcrp1 (Abcg2) multidrug transporter in mouse cell lines selected for Doxorubicin resistance. | 2002 Apr 15 |
1 |
| 21 |
12089223 | Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. | 2002 Jul 1 |
2 |
| 22 |
11036110 | Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. | 2000 Oct 18 |
6 |
| 23 |
10485464 | The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. | 1999 Sep 1 |
3 |